Lataa...
Spotlight on ixazomib: potential in the treatment of multiple myeloma
Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major ch...
Tallennettuna:
| Julkaisussa: | Drug Des Devel Ther |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4714737/ https://ncbi.nlm.nih.gov/pubmed/26811670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S93602 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|